Current Report Filing (8-k)
January 07 2020 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): December 13, 2019
REGEN BIOPHARMA, INC.
(Exact name of small business issuer
as specified in its charter)
Nevada
|
45-5192997
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa,
California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On
December 13, 2019 a complaint was filed in the Superior Court of California, County of San Diego against Regen Biopharma,
Inc. (“Company”) , the Company’s Chairman, Zander Therapeutics Inc (“Zander”), and Does
1-50 by ChemDiv, Inc. (“Plaintiff”) alleging Breach of Contract, Unfair Business Practices under the California
Business and Professions Code, and Bad Faith Denial of a Contract ( alleged solely against the Company and DOE defendants)
stemming from contract research work performed by the Plaintiff for the Company and contract research performed by the Plaintiff
for Zander. The Plaintiff is also seeking a declaration from the court that the Plaintiff retains full and complete ownership,
title, use, and all rights without any limits to the work, tangible property, intellectual property, and any other product or
by-product of the work performed by Plaintiff for the Company and Zander. The action arises from approximately $1.2 million dollars
of unpaid invoices (“Unpaid Invoices”) due and payable to the Plaintiff. The Company asserts that no portion of the
Unpaid Invoices is due and payable by the Company and the Company believes that upon a full review of the facts and the issues,
there are other issues and claims that the Company reserves the right to assert.
Although the Company believes
this legal proceeding as it pertains to the Company has no merit, it is not possible to predict the ultimate outcome of this legal
action. The outcome of this legal proceeding may adversely affect the Company’s financial condition and operations
and may also result in loss of control by the Company of intellectual property controlled by the Company.
The Company and Zander are
under common control. David Koos serves as Chief Executive Officer and Chairman of the Board of Zander and the Company. Todd S.
Caven serves as Chief Financial Officer and is a Director of Zander and the Company.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC.
|
|
|
Dated:
January 6, 2020
|
By: /s/
David Koos
|
|
David
Koos
|
|
Chief
Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2023 to Apr 2024